SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
Jemperli aims for ovarian white space
But, like Merck two weeks ago, GSK has failed to hit overall survival.
ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
